Gender-associated expression of tumor markers and a small gene set in breast carcinoma

Breast

Volumn 23, Issue 3, 2014, Pages 226-233

  Andres, Sarah A ^a   Smolenkova, Irina A ^a   Wittliff, James L ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Estrogen receptor; Male breast cancer; Progestin receptor

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER; ARYLAMINE ACETYLTRANSFERASE; EGFR PROTEIN, HUMAN; GLYCOPROTEIN GP 130; HER2-NEU-DERIVED PEPTIDE (654-662); IL6ST PROTEIN, HUMAN; ISOENZYME; N-ACETYLTRANSFERASE 1; PEPTIDE FRAGMENT; RABEP1 PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IL6ST GENE; LRBA GENE; MALE; NAT1 GENE; ONCOGENE; PLK1 GENE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RABEP1 GENE; SEX DIFFERENCE; TBC1DE9 GENE; AGE; BIOPSY; BREAST NEOPLASMS; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY;

AGE FACTORS; ARYLAMINE N-ACETYLTRANSFERASE; BIOPSY; BREAST NEOPLASMS; CATHEPSIN D; CYTOKINE RECEPTOR GP130; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; VESICULAR TRANSPORT PROTEINS;

EID: 84899931580     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.02.007     Document Type: Article

References (52)

1. American Cancer Society Breast cancer facts & figures 2011-2012 2012, American Cancer Society, Inc, Atlanta, GA.
2. Everson R.B., Lippman M.E., Thompson E.B., McGuire W.L., Wittliff J.L., De Sombre E.R., et al. Clinical correlations of steroid receptors and male breast cancer. Cancer Res 1980, 40:991-997.
3. Wittliff J.L. Specific receptors of the steroid hormones in breast cancer. Semin Oncol 1974, 1:109-118.
4. Williams W.L., Powers M., Wagman L.D. Cancer of the male breast: a review. JNatl Med Assoc 1996, 88:439-443.
5. Fisher B., Redmond C., Brown A., Wolmark N., Wittliff J.L., Fisher E.R., et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. NEngl J Med 1981, 305:1-6.
6. Fisher B., Redmond C., Brown A., Wickerham D.L., Wolmark N., Allegra J., et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. JClin Oncol 1983, 1:227-241.
7. Winchester D.J. Male breast Cancer. Cancer of the breast 2002, 951-958. Sauders, St. Louis, MO. W.L. Donegan, J.S. Spratt (Eds.).
8. Anderson W.F., Jatoi I., Tse J., Rosenberg P.S. Male breast cancer: a population-based comparison with female breast cancer. JClin Oncol 2010, 28:232-239.
9. Haraldsson K., Loman N., Zhang Q.X., Johannsson O., Olsson H., Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998, 58:1367-1371.
10. Kwiatkowska E., Teresiak M., Filas V., Karczewska A., Breborowicz D., Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 2003, 9:4452-4459.
11. Lester S.C. The breast. Robbins and Cotran pathologic basis of disease 2005, 1119-1154. Elsevier Inc, Philadelphia, PA. V. Kumar, A.K. Abbas, N. Fausto (Eds.).
12. Tai Y.C., Domchek S., Parmigiani G., Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. JNatl Cancer Inst 2007, 99:1811-1814.
13. MacLean H.E., Brown R.W., Beilin J., Warne G.L., Zajac J.D. Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Res Treat 2004, 88:239-246.
14. Song Y.N., Geng J.S., Liu T., Zhong Z.B., Liu Y., Xia B.S., et al. Long CAG repeat sequence and protein expression of androgen receptor considered as prognostic indicators in male breast carcinoma. PLoS One 2012, 7:e52271.
15. Fackenthal J.D., Marsh D.J., Richardson A.L., Cummings S.A., Eng C., Robinson B.G., et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. JMed Genet 2001, 38:159-164.
16. Johansson I., Nilsson C., Berglund P., et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 2012, 14:R31.
17. Callari M., Cappelletti V., De Cecco L., Musella V., Miodini P., Veneroni S., et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2011, 127:601-610.
18. Wittliff J.L., Pasic R., Bland K.I. Steroid and peptide hormone receptors identified in breast tissue. The breast: comprehensive management of benign and malignant diseases 1998, 900-936. W. B. Saunders Co, Philadelphia, PA. K.I. Bland, E.M. Copeland (Eds.).
19. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). JNatl Cancer Inst 2005, 97:1180-1184.
20. Andres S.A., Wittliff J.L. Co-expression of genes with estrogen receptor-a and progesterone erceptor in human breast carcinoma tissue. Horm Mol Biol Clin Investig 2012, 12:377-390.
21. Kerr D.A., Wittliff J.L. Afive-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen. Horm Cancer 2011, 2:261-271.
22. Wittliff J.L., Raffelsberger W. Mechanisms of signal transduction: sex hormones, their receptors and clinical utility. JClin Ligand Assay 1995, 18:211-235.
23. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JClin Oncol 2010, 28:2784-2795.
24. Fleisher M., Dnistrian A.M., Sturgeon C.M., Wittliff J.L. Practice guidelines and recommendations for use of tumor markers in the clinic. Tumor markers: physiology, pathobiology, technology and clinical applications 2002, 33-63. AACC Press, Washington D.C. D.P. Diamandis, H.A. Fritsche, H. Lilja, D.W. Chan, M.K. Schwartz (Eds.).
25. Pasic R., Djulbegovic B., Wittliff J.L. Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. JClin Lab Anal 1990, 4:430-436.
26. Fekete M., Wittliff J.L., Schally A.V. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. JClin Lab Anal 1989, 3:137-147.
27. Shaheen R.M., Miseljic S., Wiehle R.D., Wittliff J.L. Relation between cathepsin D expression and other prognostic factors in breast carcinomas. Clin Chem 1995, 41:1585-1591.
28. Andres S.A., Brock G.N., Wittliff J.L. Interrogating differences in expression of targeted gene sets to predict breast cancer outcome. BMC Cancer 2013, 13:326.
29. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. JClin Oncol 2005, 23:732-740.
30. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., et al. Amultigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
31. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003, 100:5974-5979.
32. Ma X.J., Wang W., Salunga R., Tuggle J.T., Stecker K., Baer T.M., et al. Gene expression associated with clinical outcome in breast cancer via laser capture microdissection. Breast Cancer Res Treat 2003, 82:S15.
33. Ma X.J., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., et al. Atwo-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
34. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. Amolecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
35. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
36. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393-10398.
37. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
38. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
39. Andres S.A., Wittliff J.L. Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue. Endocrine 2011, 40:212-221.
40. Giordano S.H., Cohen D.S., Buzdar A.U., Perkins G., Hortobagyi G.N. Breast carcinoma in men: a population-based study. Cancer 2004, 101:51-57.
41. Gomez-Raposo C., Zambrana T.F., Sereno M.M., Lopez G.M., Casado E. Male breast cancer. Cancer Treat Rev 2010, 36:451-457.
42. Kardinal C.G. Hormonal and endocrine therapy of breast cancer. Cancer of the Breast 2002, Saunders/Elsevier Science, Philadelphia, PA, p. 693-958. W.L. Donegan, J.S. Spratt (Eds.).
43. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. JClin Oncol 2013, 3997-4013.
44. Borgen P.I., Senie R.T., McKinnon W.M., Rosen P.P. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997, 4:385-388.
45. Adami H.O., Holmberg L., Malker B., Ries L. Long-term survival in 406 males with breast cancer. Br J Cancer 1985, 52:99-103.
46. Rudan I., Rudan N., Strnad M. Differences between male and female breast cancer. I. Epidemiological features. Acta Med Croat 1995, 49:117-120.
47. Scheike O. Male breast cancer. 5. Clinical manifestations in 257 cases in Denmark. Br J Cancer 1973, 28:552-561.
48. Fentiman I.S., Fourquet A., Hortobagyi G.N. Male breast cancer. Lancet 2006, 367:595-604.
49. Zygogianni A.G., Kyrgias G., Gennatas C., Ilknur A., Armonis V., Tolia M., et al. Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev 2012, 13:15-19.
50. Rudlowski C. Male breast Cancer. Breast Care (Basel) 2008, 3:183-189.
51. Foekens J.A., Look M.P., Bolt-de Vries J., Meijer-van Gelder M.E., van Putten W.L., Klijn J.G. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999, 79:300-307.
52. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25:5287-5312.